Latest Insider Transactions at Theravance Biopharma, Inc. (TBPH)
This section provides a real-time view of insider transactions for Theravance Biopharma, Inc. (TBPH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Theravance Biopharma, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Theravance Biopharma, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 20
2022
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
15,804
-1.11%
|
$158,040
$10.85 P/Share
|
|
Nov 18
2022
|
Andrew A. Hindman SVP, CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
65,000
-13.69%
|
$715,000
$11.02 P/Share
|
|
Nov 16
2022
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Payment of exercise price or tax liability
|
Direct |
2,800
-0.81%
|
$30,800
$11.2 P/Share
|
|
Sep 16
2022
|
Glaxosmithkline PLC |
SELL
Other acquisition or disposition
|
Indirect |
9,644,807
-100.0%
|
$86,803,263
$9.75 P/Share
|
|
Aug 19
2022
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
15,804
-1.1%
|
$142,236
$9.34 P/Share
|
|
Aug 19
2022
|
Andrew A. Hindman SVP, CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
25,676
-5.14%
|
$231,084
$9.34 P/Share
|
|
Aug 19
2022
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Payment of exercise price or tax liability
|
Direct |
18,991
-5.21%
|
$170,919
$9.34 P/Share
|
|
Aug 19
2022
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
SELL
Payment of exercise price or tax liability
|
Direct |
10,413
-3.16%
|
$93,717
$9.34 P/Share
|
|
Aug 16
2022
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Open market or private sale
|
Direct |
4,906
-1.33%
|
$44,154
$9.71 P/Share
|
|
Aug 09
2022
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Open market or private sale
|
Direct |
15,086
-3.92%
|
$120,688
$8.79 P/Share
|
|
Jul 25
2022
|
Andrew A. Hindman SVP, CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+3.85%
|
-
|
|
May 23
2022
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
SELL
Open market or private sale
|
Direct |
1,081
-0.33%
|
$8,648
$8.93 P/Share
|
|
May 20
2022
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
SELL
Payment of exercise price or tax liability
|
Direct |
2,200
-0.66%
|
$17,600
$8.74 P/Share
|
|
May 20
2022
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Payment of exercise price or tax liability
|
Direct |
3,947
-1.02%
|
$31,576
$8.74 P/Share
|
|
May 20
2022
|
Andrew A. Hindman SVP, CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,365
-0.7%
|
$26,920
$8.74 P/Share
|
|
May 20
2022
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
11,025
-0.76%
|
$88,200
$8.74 P/Share
|
|
Apr 26
2022
|
Alsup Laurie Smaldone |
BUY
Grant, award, or other acquisition
|
Direct |
9,852
+18.07%
|
-
|
|
Apr 26
2022
|
Eran Broshy |
BUY
Grant, award, or other acquisition
|
Direct |
9,852
+13.93%
|
-
|
|
Apr 26
2022
|
Burton G Malkiel |
BUY
Grant, award, or other acquisition
|
Direct |
9,852
+9.72%
|
-
|
|
Apr 26
2022
|
Dean J Mitchell |
BUY
Grant, award, or other acquisition
|
Direct |
9,852
+13.93%
|
-
|
|
Apr 26
2022
|
Donal O'Connor |
BUY
Grant, award, or other acquisition
|
Direct |
9,852
+15.46%
|
-
|
|
Apr 26
2022
|
Deepika Pakianathan |
BUY
Grant, award, or other acquisition
|
Direct |
9,852
+26.2%
|
-
|
|
Apr 26
2022
|
William D Young |
BUY
Grant, award, or other acquisition
|
Direct |
9,852
+11.21%
|
-
|
|
Feb 28
2022
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
SELL
Open market or private sale
|
Direct |
2,356
-0.7%
|
$23,560
$10.16 P/Share
|
|
Feb 25
2022
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
170,000
+10.5%
|
-
|
|
Feb 18
2022
|
Ann Brady PRESIDENT, TBIL |
SELL
Payment of exercise price or tax liability
|
Direct |
8,369
-7.05%
|
$75,321
$9.61 P/Share
|
|
Feb 18
2022
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
SELL
Payment of exercise price or tax liability
|
Direct |
11,824
-3.4%
|
$106,416
$9.61 P/Share
|
|
Feb 18
2022
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Payment of exercise price or tax liability
|
Direct |
20,377
-4.98%
|
$183,393
$9.61 P/Share
|
|
Feb 18
2022
|
Andrew A. Hindman SVP, CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
25,973
-5.12%
|
$233,757
$9.61 P/Share
|
|
Feb 18
2022
|
Kenneth R Pitzer SVP, PROD STRAT & COMM PLNG |
SELL
Payment of exercise price or tax liability
|
Direct |
27,299
-6.7%
|
$245,691
$9.61 P/Share
|
|
Feb 18
2022
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
22,710
-1.74%
|
$204,390
$9.61 P/Share
|
|
Feb 07
2022
|
Kenneth R Pitzer SVP, PROD STRAT & COMM PLNG |
BUY
Grant, award, or other acquisition
|
Direct |
52,000
+11.32%
|
-
|
|
Dec 14
2021
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+7.33%
|
-
|
|
Dec 02
2021
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
BUY
Grant, award, or other acquisition
|
Direct |
240,000
+36.98%
|
-
|
|
Dec 02
2021
|
Andrew A. Hindman SVP, CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
340,000
+40.13%
|
-
|
|
Nov 19
2021
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
11,404
-0.87%
|
$91,232
$8.36 P/Share
|
|
Nov 19
2021
|
Vijay Sabesan SVP, TECHNICAL OPERATIONS |
SELL
Payment of exercise price or tax liability
|
Direct |
5,191
-2.16%
|
$41,528
$8.36 P/Share
|
|
Nov 19
2021
|
Philip D Worboys SVP, RESEARCH & TRANSL SCIENCE |
SELL
Payment of exercise price or tax liability
|
Direct |
4,310
-1.29%
|
$34,480
$8.36 P/Share
|
|
Nov 19
2021
|
Andrew A. Hindman SVP, CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,350
-0.8%
|
$10,800
$8.36 P/Share
|
|
Nov 19
2021
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Payment of exercise price or tax liability
|
Direct |
4,263
-2.46%
|
$34,104
$8.36 P/Share
|
|
Nov 19
2021
|
Kenneth R Pitzer SVP, PROD STRAT & COMM PLNG |
SELL
Payment of exercise price or tax liability
|
Direct |
4,310
-1.2%
|
$34,480
$8.36 P/Share
|
|
Nov 19
2021
|
Frank Pasqualone SVP, CHIEF BUSINESS OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,779
-0.87%
|
$30,232
$8.36 P/Share
|
|
Nov 19
2021
|
Ann Brady PRESIDENT, TBIL |
SELL
Payment of exercise price or tax liability
|
Direct |
3,169
-2.6%
|
$25,352
$8.36 P/Share
|
|
Aug 20
2021
|
Ann Brady PRESIDENT, TBIL |
SELL
Payment of exercise price or tax liability
|
Direct |
3,169
-2.53%
|
$44,366
$14.05 P/Share
|
|
Aug 20
2021
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Payment of exercise price or tax liability
|
Direct |
6,819
-3.79%
|
$95,466
$14.05 P/Share
|
|
Aug 20
2021
|
Andrew A. Hindman SVP, CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
17,464
-9.45%
|
$244,496
$14.05 P/Share
|
|
Aug 20
2021
|
Frank Pasqualone SVP, CHIEF BUSINESS OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,779
-0.86%
|
$52,906
$14.05 P/Share
|
|
Aug 20
2021
|
Kenneth R Pitzer SVP, PROD STRAT & COMM PLNG |
SELL
Payment of exercise price or tax liability
|
Direct |
4,307
-1.18%
|
$60,298
$14.05 P/Share
|
|
Aug 20
2021
|
Vijay Sabesan SVP, TECHNICAL OPERATIONS |
SELL
Payment of exercise price or tax liability
|
Direct |
5,193
-2.11%
|
$72,702
$14.05 P/Share
|
|
Aug 20
2021
|
Bradford J Shafer EVP, Gen. Counsel, Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
4,307
-1.53%
|
$60,298
$14.05 P/Share
|